Skip to main content

Table 1 Perioperative features of RALP patients based on pathologic prostate weight

From: Impact of prostate weight on perioperative outcomes of robot-assisted laparoscopic prostatectomy with a posterior approach to the seminal vesicle

Variable

<30

≥30, <50

≥50, <80

≥80

P Value

Patients (n)

19

143

51

6

 

Prostate weight (g)

24.5 (18–29)

38.5 (30–48)

58.6 (50–78)

97.7 (86–110)

<0.01

Mean age (y)

65.9 (50–76)

66.5 (49–75)

67.6 (41–75)

67.7 (60–72)

0.63

Mean PSA (ng/mL)

9.7

7.5

9.0

9.9

0.30

BMI

23.7

23.3

23.4

25.3

0.08

Preoperative Gleason score

   

  5–6

3 (15.8%)

39 (27.3%)

24 (47.1%)

4 (66.7%)

<0.01

  7

14 (73.7%)

59 (41.3%)

11 (21.6%)

2 (33.3%)

 

  8–9

2 (10.5%)

45 (31.5%)

16 (31.4%)

0

 

Clinical stage

    

  T1c

4 (21.1%)

40 (28.0%)

15 (29.4%)

5 (83.3%)

0.34

  T2a

4 (21.1%)

38 (26.6%)

16 (31.4%)

1 (16.7%)

 

  T2b

4 (21.1%)

12 (8.4%)

4 (7.8%)

0

 

  T2c

7 (36.8%)

44 (30.8%)

14 (27.5%)

0

 

  T3a

0

8 (5.6%)

1 (2.0%)

0

 

  T3b

0

1 (0.7%)

1 (2.0%)

0

 

Nerve sparing

     

  None

14 (73.7%)

113 (79.0%)

43 (84.3%)

6 (100.0%)

0.62

  Unilateral

3 (15.8%)

24 (16.8%)

5 (9.8%)

0

 

  Bilateral

2 (10.5%)

6 (4.2%)

3 (5.9%)

0

 

Estimated blood loss (mL)

241.8

304.2

259.8

586.0

0.05

Transfusion

1 (5.3%)

6 (4.2%)

2 (3.9%)

0

1.21

Mean total operative time (min)

223.7

219.6

219.3

270.7

<0.01

Mean robotic time (min)

165.4

163.8

162.4

216.5

<0.01

Mean anastomosis time (min)

26.5

25.7

23.0

32.5

0.13

Mean Foley catheterization (days)

7.58

7.76

8.36

8.83

0.54

Pathological stage

    

  pT2a

1 (5.3%)

18 (12.6%)

14 (27.5%)

4 (66.7%)

<0.01

  pT2b

3 (15.8%)

2 (1.4%)

1 (2.0%)

0

 

  pT2c

13 (68.4%)

96 (67.1%)

29 (56.9%)

2 (33.3%)

 

  pT3a

1 (5.3%)

11 (7.7%)

5 (9.8%)

0

 

  pT3b

1 (5.3%)

16 (11.2%)

2 (3.9%)

0

 

Positive margins

7/19

54/143

13/51

1/6

0.33

(36.8%)

(37.8%)

(25.5%)

(16.7%)

  pT2

5/17

39/116

9/44

1/6

0.37

(29.4%)

(33.6%)

(20.5%)

(16.7%)

  pT3

2/2

15/27

4/7

0/0

0.47

(100.0%)

(55.6%)

(57.1%)

(0.0%)

Mean follow-up (mo)

12.0

11.8

10.6

9.7

0.43